{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:42:38Z","timestamp":1788914558905,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40265-022-01680-9","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T11:02:46Z","timestamp":1645614166000},"page":"469-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Olverembatinib: First Approval"],"prefix":"10.1007","volume":"82","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"issue":"19","key":"1680_CR1","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, Goncalves AC, Rutella S, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers. 2021;13(19):4820.","journal-title":"Cancers"},{"issue":"4","key":"1680_CR2","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37(4):530\u201342.","journal-title":"Cancer Cell"},{"issue":"6","key":"1680_CR3","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11899-021-00658-w","volume":"16","author":"N Javidi-Sharifi","year":"2021","unstructured":"Javidi-Sharifi N, Hobbs G. Future directions in chronic phase CML treatment. Curr Hematol Malig Rep. 2021;16(6):500\u20138.","journal-title":"Curr Hematol Malig Rep"},{"issue":"8","key":"1680_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11912-021-01087-x","volume":"23","author":"M Shoukier","year":"2021","unstructured":"Shoukier M, Kubiak M, Cortes J. Review of new-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Curr Oncol Rep. 2021;23(8):91.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"1680_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1021\/jm301581y","volume":"56","author":"X Ren","year":"2013","unstructured":"Ren X, Pan X, Zhang Z, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013;56(3):879\u201394.","journal-title":"J Med Chem"},{"issue":"Suppl 1","key":"1680_CR6","first-page":"3598","volume":"138","author":"Q Jiang","year":"2021","unstructured":"Jiang Q, Dayu S, Zongru L, et al. Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant BCR-ABL1 T315I-mutated chronic- and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP). Blood. 2021;138(Suppl 1):3598.","journal-title":"Blood"},{"key":"1680_CR7","unstructured":"Ascentage Pharma. Ascentage Pharma and Innovent Biologics announce approval for China\u2019s first third-generation BCR-ABL TKI olverembatinib, marking a clinical breakthrough in the treatment of chronic myeloid leukemia [media release]. 30 Nov 2021. https:\/\/www.ascentagepharma.com\/press-releases\/ascentage-pharma-and-innovent-biologics-announce-approval-for-chinas-first-third-generation-bcr-abl-tki-olverembatinib-marking-a-clinical-breakthrough-in-the-treatment-of-chronic-myeloid-leu-2\/."},{"key":"1680_CR8","unstructured":"Ascentage Pharma. Olverembatinib (HQP1351): Chinese prescribing information. 2021"},{"key":"1680_CR9","unstructured":"Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences. http:\/\/english.gibh.cas.cn\/Comment\/201305\/t20130527_102502.html. Accessed 20 Dec 2021."},{"key":"1680_CR10","unstructured":"Ascentage Pharma. 2019 Annual report. https:\/\/www.ascentagepharma.com\/wp-content\/uploads\/2020\/08\/2020041700666.pdf. Accessed 20 Dec 2021."},{"key":"1680_CR11","unstructured":"Ascentage Pharma, MD Anderson Cancer Center. Ascentage Pharma and MD Anderson Cancer Center announce strategic alliance in cancer drug development [media release]. 6 Jan 2019. https:\/\/www.ascentagepharma.com\/news\/press-releases\/."},{"key":"1680_CR12","unstructured":"Innovent Biologics. Ascentage Pharma and Innovent Biologics reach multifaceted strategic agreement totaling US$245 million including commercialization of olverembatinib (HQP1351) in China, joint clinical development of lisaftoclax (APG-2575) and equity investment [media release]. 14 Jul 2021. https:\/\/www.ascentagepharma.com\/news\/press-releases\/."},{"issue":"4","key":"1680_CR13","doi-asserted-by":"publisher","first-page":"100766","DOI":"10.1016\/j.tranon.2020.100766","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang L, Tang X, et al. GZD824 as a FLT3, FGFR1 and PDGFR\u03b1 inhibitor against leukemia in vitro and in vivo. Transl Oncol. 2020;13(4):100766.","journal-title":"Transl Oncol"},{"key":"1680_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13578-019-0351-6","volume":"9","author":"X Liu","year":"2019","unstructured":"Liu X, Wang G, Yan X, et al. Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019;9:88.","journal-title":"Cell Biosci"},{"issue":"Suppl. 1","key":"1680_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood-2018-99-119142","volume":"132","author":"Q Jiang","year":"2018","unstructured":"Jiang Q, Huang XJ, Chen Z, et al. Safety and efficacy of HQP1351, a 3rd generation oral BCR-ABL inhibitor in patients with tyrosine kinase inhibitor-resistant chronic myelogenous leukemia: preliminary results of phase I study [abstract]. Blood. 2018;132(Suppl. 1):791.","journal-title":"Blood"},{"issue":"50","key":"1680_CR16","doi-asserted-by":"publisher","first-page":"87002","DOI":"10.18632\/oncotarget.10881","volume":"8","author":"W Ye","year":"2017","unstructured":"Ye W, Jiang Z, Lu X, et al. GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K\/AKT pathways. Oncotarget. 2017;8(50):87002\u201315.","journal-title":"Oncotarget"},{"issue":"14","key":"1680_CR17","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1002\/cam4.4041","volume":"10","author":"K Jiang","year":"2021","unstructured":"Jiang K, Tang X, Guo J, et al. GZD824 overcomes FGFR1-V561F\/M mutant resistance in vitro and in vivo. Cancer Med. 2021;10(14):4874\u201384.","journal-title":"Cancer Med"},{"issue":"1","key":"1680_CR18","doi-asserted-by":"publisher","first-page":"101244","DOI":"10.1016\/j.tranon.2021.101244","volume":"15","author":"DD Fang","year":"2021","unstructured":"Fang DD, Zhu H, Tang Q, et al. FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia. Transl Oncol. 2021;15(1):101244.","journal-title":"Transl Oncol"},{"issue":"13 Suppl","key":"1680_CR19","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1158\/1538-7445.AM2021-1463","volume":"81","author":"G Wang","year":"2021","unstructured":"Wang G, Lv J, Tang C, et al. ATP-site inhibitor olverembatinib, HQP1351, enhanced the effect of allosteric inhibitor on the resistance conferred by the compound mutations of BCR-ABL [abstract]. Cancer Res. 2021;81(13 Suppl):1463.","journal-title":"Cancer Res"},{"key":"1680_CR20","doi-asserted-by":"crossref","unstructured":"Fang DD, Tang Q, Wang Q, et al. Synergy of tyrosine kinase inhibitor HQP1351 and MDM2-P53 antagonist, APG-115, in preclinical models of FLT3 mutant and TP53 wild-type acute myeloid leukemia [abstract]. Cancer Res. 2020;80(16 Suppl):4217.","DOI":"10.1158\/1538-7445.AM2020-4217"},{"issue":"Suppl 1","key":"1680_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1182\/blood-2019-124295","volume":"134","author":"Q Jiang","year":"2019","unstructured":"Jiang Q, Huang X, Chen Z, et al. An updated safety and efficacy results of phase 1 study of HQP1351, a novel 3rd generation of BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI resistant chronic myeloid leukemia [abstract]. Blood. 2019;134(Suppl 1):493.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1680_CR22","first-page":"5","volume":"136","author":"M Lu","year":"2020","unstructured":"Lu M, Deng C, Xiong Y, et al. Exposure-response (E-R) analysis of olverembatinib (HQP1351) in Chinese patients with chronic myeloid leukemia (CML) [abstract]. Blood. 2020;136(Suppl 1):5\u20136.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1680_CR23","first-page":"311","volume":"138","author":"Q Jiang","year":"2021","unstructured":"Jiang Q, Shi D, Li Z, et al. Updated safety and efficacy results of phase 1 study of olverembatinib (HQP1351), a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia (CML) [abstract plus presentation]. Blood. 2021;138(Suppl 1):311.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1680_CR24","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1182\/blood-2021-152693","volume":"138","author":"EJ Jabbour","year":"2021","unstructured":"Jabbour EJ, Kantarjian H, Issa GC, et al. Trial in Progress: Phase 1b bridging study of the pharmacokinetics (PK), safety, and efficacy of orally administered olverembatinib (HQP1351) in patients with refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [abstract]. Blood. 2021;138(Suppl 1):2551.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01680-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01680-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01680-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T19:20:36Z","timestamp":1674847236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01680-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01680-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"assertion":[{"value":"23 February 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}